Reform begins with updating the evidence standards used by guideline committees. Currently, many protocols rely on narrow clinical trials that focus almost exclusively on estrogen. To change this, medical boards must actively review emerging data regarding how androgen levels influence bone density, libido, and cognitive clarity in postmenopausal women.
Healthcare systems also need to address the training gap. Many primary care physicians feel uncomfortable prescribing testosterone because they lack specific guidance on dosing and monitoring. Systems should integrate standardized protocols into electronic health records. These digital tools can prompt doctors to check free testosterone levels and provide clear pathways for titration. This reduces guesswork.
Insurance coverage plays a major role too. Even if a doctor writes a prescription, many providers deny claims for testosterone therapy in women. Payers must align their coverage policies with updated clinical guidelines to ensure patients can actually access the treatment. When coverage matches the science, adoption increases. We need a shift from a 'one-size-fits-all' estrogen model to a more personalized, multi-hormone approach that recognizes the biological needs of diverse patients.
